• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Alpha Interferons (Roferon-A, Intron A, Rebetron Combination Therapy)

Intron A (Interferon alfa 2b, recombinant)
Rebetron Combination Therapy (Rebetrol (Ribavirin, USP) Capsules and Intron A)
Roferon-A (Interferon alfa-2a, recombinant)

Audience: Oncologists and other Healthcare professionals

Healthcare professionals are advised of important safety information for all alpha interferons. A BOXED WARNING has been added regarding the occurrence of neuropsychiatric, autoimmune, ischemic, and infectious disorders in patients taking alpha interferons; additional safety information and direction for patient monitoring is also provided in the WARNINGS section of the prescribing information.

[March 14, 2002 - Letter - Roche]